Comparative Pharmacology
Head-to-head clinical analysis: LEDERCILLIN VK versus NAFCILLIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEDERCILLIN VK versus NAFCILLIN SODIUM.
LEDERCILLIN VK vs NAFCILLIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin V is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It is bactericidal against susceptible organisms during the active growth phase.
Nafcillin exerts bactericidal activity by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
1-2 g IV every 4 hours; or 1-2 g IM every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life is 0.5 hours (range 0.4–0.6 hours) in adults with normal renal function. In severe renal impairment (CrCl <10 mL/min), half-life extends to ~4 hours.
Approximately 0.5 hour (30 minutes) in adults with normal renal function; prolonged to 1-2 hours in neonates or severe renal impairment. Clinically relevant for dosing every 4-6 hours.
Renal elimination predominantly via tubular secretion of unchanged drug (>90% of absorbed dose). Approximately 20-40% of an oral dose is recovered in urine as unchanged penicillin V. Biliary excretion accounts for <1% of elimination; fecal elimination is negligible.
Primarily renal (30-40% unchanged) and hepatic/biliary elimination. Approximately 10-15% excreted in bile via feces.
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic